AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31016412 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (SBT)
Number of subjects: 100
Study 31016412 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm thickness evolution patterns
Number of subjects: 100
Study 31016412 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm thickening evolution
Number of subjects: 100
Study 31016412 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation failure
Number of subjects: 100
Study 31016505 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-prescribed physical activity (physically active group)
Number of subjects: 0
Study 31016505 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group (control)
Number of subjects: 0
Study 31016722 — intervention group
Group type: EXPERIMENTAL
Intervention: Later high school start time (8:30 AM or later)
Number of subjects: 256
Study 31016722 — intervention group
Group type: COMPARATOR
Intervention: Earlier high school start time (before 8:30 AM)
Number of subjects: 256
Study 31016855 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic treatment
Number of subjects: 103
Study 31016855 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment
Number of subjects: 103
Study 31017022 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab single-use prefilled syringe
Number of subjects: 0
Study 31017850 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine at a 6-month interval
Number of subjects: 204
Study 31017850 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine at a 3-8 year interval
Number of subjects: 204
Study 31017850 — intervention group
Group type: COMPARATOR
Intervention: 4vHPV vaccine (one dose) followed by 9vHPV (after 3-8 years)
Number of subjects: 204
Study 31018069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagraxofusp at a dose of 12 μg per kilogram
Number of subjects: 47
Study 31018069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagraxofusp at a dose of 7 μg per kilogram
Number of subjects: 47
Study 31018069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagraxofusp (both doses)
Number of subjects: 47
Study 31018069 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Number of subjects: 47
Study 31018667 — intervention group
Group type: EXPERIMENTAL
Intervention: AA homozygotes for PEAR1 rs12041331
Number of subjects: 2439
Study 31018667 — intervention group
Group type: COMPARATOR
Intervention: GG homozygotes for PEAR1 rs12041331
Number of subjects: 2439
Study 31018667 — intervention group
Group type: COMPARATOR
Intervention: GA heterozygotes for PEAR1 rs12041331
Number of subjects: 2439
Study 31018840 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin Choice Conversation Aid (SCCA)
Number of subjects: 196
Study 31019106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen (12 mg, single-dose level)
Number of subjects: 28
Study 31019106 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 28
Study 31019170 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal D-dimer levels
Number of subjects: 718
Study 31019170 — intervention group
Group type: COMPARATOR
Intervention: Normal D-dimer levels
Number of subjects: 718
Study 31020361 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal colonization with Candida spp.
Number of subjects: 213
Study 31020361 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodes of VAP
Number of subjects: 213
Study 31020630 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQ-F (Pain Sensitivity Questionnaire - French version)
Number of subjects: 146
Study 31020755 — intervention group
Group type: EXPERIMENTAL
Intervention: Code-based algorithm for opioid-related overdoses
Number of subjects: 475000
Study 31020755 — intervention group
Group type: EXPERIMENTAL
Intervention: Code-based algorithm for heroin-involved overdoses
Number of subjects: 475000
Study 31020755 — intervention group
Group type: EXPERIMENTAL
Intervention: Code-based algorithm for suicide/suicide attempt classifications
Number of subjects: 475000
Study 31020755 — intervention group
Group type: EXPERIMENTAL
Intervention: Code-based algorithm for substance abuse-involved classification
Number of subjects: 475000
Study 31020755 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-enhanced algorithms for suicides/suicide attempts and abuse-related overdoses
Number of subjects: 475000
Study 31020755 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-related overdose algorithm across portability assessment sites
Number of subjects: 475000
Study 31020755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-site sensitivity for heroin-involved overdose
Number of subjects: 475000
Study 31020819 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 31020819 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 0
Study 31021250 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Cognitive Training
Number of subjects: 0
Study 31021250 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31022095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with legumes
Number of subjects: 693
Study 31022095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with legumes in Masenjere
Number of subjects: 693
Study 31022095 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with legumes in Limera
Number of subjects: 693
Study 31022095 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Masenjere to Limera
Number of subjects: 693
Study 31022095 — intervention group
Group type: COMPARATOR
Intervention: Comparison of water quality and food insecurity
Number of subjects: 693
Study 31023100 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant axitinib + avelumab
Number of subjects: 40
Study 31023166 — intervention group
Group type: EXPERIMENTAL
Intervention: manual-traced IMT (mt-IMT)
Number of subjects: 5467
Study 31023166 — intervention group
Group type: EXPERIMENTAL
Intervention: edge-detected IMT (ed-IMT)
Number of subjects: 5467
Study 31023296 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy administered by injection every 4 weeks
Number of subjects: 15
Study 31023377 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant hypertension
Number of subjects: 15656
Study 31023377 — intervention group
Group type: COMPARATOR
Intervention: Controlled hypertension
Number of subjects: 15656
Study 31023377 — intervention group
Group type: COMPARATOR
Intervention: Controlled resistant hypertension
Number of subjects: 15656
Study 31023700 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg/day monotherapy
Number of subjects: 436
Study 31024007 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of clinical-grade human neural stem cells (hNSCs)
Number of subjects: 0
Study 31024007 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated SOD1 rats and those treated with HBSS)
Number of subjects: 0
Study 31024276 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state functional connectivity (FC) analysis in ASD males and females
Number of subjects: 120
Study 31024276 — intervention group
Group type: COMPARATOR
Intervention: Resting-state functional connectivity (FC) analysis in control males and females
Number of subjects: 120
Study 31024430 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive Slides on Axial View
Number of subjects: 0
Study 31024430 — intervention group
Group type: COMPARATOR
Intervention: Transversal Diameter
Number of subjects: 0
Study 31024436 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-injury comorbidities
Number of subjects: 0
Study 31024734 — intervention group
Group type: EXPERIMENTAL
Intervention: HA + mannitol
Number of subjects: 22
Study 31024734 — intervention group
Group type: COMPARATOR
Intervention: HA
Number of subjects: 22
Study 31024734 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 31024845 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose to reconstructed breast
Number of subjects: 0
Study 31024845 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiation dose specified)
Number of subjects: 0
Study 31024978 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with HEV239 vaccine
Number of subjects: 167
Study 31024978 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural infection with HEV
Number of subjects: 167
Study 31024978 — intervention group
Group type: COMPARATOR
Intervention: Comparison of vaccinated vs naturally infected
Number of subjects: 167
Study 31025045 — intervention group
Group type: EXPERIMENTAL
Intervention: Human gut microbiota transferred to germ-free NOD mice
Number of subjects: 5
Study 31025952 — intervention group
Group type: EXPERIMENTAL
Intervention: N-PDT (Flexitheralight device)
Number of subjects: 42
Study 31025952 — intervention group
Group type: COMPARATOR
Intervention: C-PDT (Aktilite CL 128 device)
Number of subjects: 42
Study 31025952 — intervention group
Group type: EXPERIMENTAL
Intervention: N-PDT
Number of subjects: 42
Study 31025953 — intervention group
Group type: EXPERIMENTAL
Intervention: PDT using the Phosistos protocol (P-PDT)
Number of subjects: 46
Study 31025953 — intervention group
Group type: COMPARATOR
Intervention: PDT using the conventional protocol (C-PDT)
Number of subjects: 46
Study 31026576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1 therapy)
Number of subjects: 37
Study 31026764 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in patient quality of life over 24 months
Number of subjects: 282
Study 31026764 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in family burden over 24 months
Number of subjects: 282
Study 31026764 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial levels of positive symptoms
Number of subjects: 282
Study 31026764 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between quality of life and family burden
Number of subjects: 282
Study 31026764 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between family burden and quality of life
Number of subjects: 282
Study 31027916 — intervention group
Group type: EXPERIMENTAL
Intervention: Abivertinib (50-350 mg twice daily or 300 mg twice daily)
Number of subjects: 30
Study 31027916 — intervention group
Group type: EXPERIMENTAL
Intervention: Abivertinib
Number of subjects: 30
Study 31028053 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-administered FAM-CAM
Number of subjects: 21
Study 31028053 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-administered Sour Seven questionnaire
Number of subjects: 21
Study 31028053 — intervention group
Group type: COMPARATOR
Intervention: Trained research assistants using Confusion Assessment Method for the ICU 7
Number of subjects: 21
Study 31028235 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural respiratory drive (NRD) measured by change in parasternal muscle electromyogram (EMGpara)
Number of subjects: 120
Study 31028235 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 120
Study 31028290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness in individuals with ASD
Number of subjects: 491
Study 31028290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness in younger individuals with ASD
Number of subjects: 491
Study 31028290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness in individuals with lower full-scale intelligence (FIQ)
Number of subjects: 491
Study 31028290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical thickness related to clinical severity
Number of subjects: 491
Study 31028495 — intervention group
Group type: EXPERIMENTAL
Intervention: EXAcerbations of COPD Tool (EXACT®) questionnaire, daily observations over a year.
Number of subjects: 127
Study 31028495 — intervention group
Group type: EXPERIMENTAL
Intervention: Markov models applied to the EXACT® item responses.
Number of subjects: 127
Study 31028495 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT model with Markovian properties.
Number of subjects: 127
Study 31028506 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system based on features associated with survival (age, smoking, CA125, SCC, KPS, EGFR status)
Number of subjects: 176
Study 31028506 — intervention group
Group type: EXPERIMENTAL
Intervention: Model validation of the scoring system
Number of subjects: 176
Study 31028506 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis of 176 patients
Number of subjects: 176
Study 31028506 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective validation in another 63 patients (NCT03363685)
Number of subjects: 176
Study 31028664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg QD
Number of subjects: 168
Study 31028664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib (various doses from 100 mg BID to 1200 mg QD)
Number of subjects: 168
Study 31028664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib (various doses)
Number of subjects: 168
Study 31028699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 17
Study 31028699 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet (BD)
Number of subjects: 17
Study 31029086 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA antigen bead assay reactivity profiles
Number of subjects: 52
Study 31029086 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifier based on continuous data and multiparameter classification method
Number of subjects: 52
Study 31030414 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg bid for 4 days, followed by apixaban 10 mg and clarithromycin 500 mg bid on day 8.
Number of subjects: 19
Study 31030414 — intervention group
Group type: COMPARATOR
Intervention: Apixaban 10 mg alone on day 1 and day 8.
Number of subjects: 19
Study 31030528 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA
Number of subjects: 6466
Study 31030969 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity levels
Number of subjects: 177
Study 31030969 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of physical activity
Number of subjects: 177
Study 31031089 — intervention group
Group type: EXPERIMENTAL
Intervention: iCAST Covered Stent
Number of subjects: 152
Study 31031265 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose opioids (increased dose over the last 14 days)
Number of subjects: 63
Study 31031265 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose opioids (no increase of dose over the last 14 days)
Number of subjects: 63
Study 31031265 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 63
Study 31031906 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 61
Study 31032113 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue capsule staining during phacoemulsification
Number of subjects: 0
Study 31032113 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification without trypan blue capsule staining (control)
Number of subjects: 0
Study 31032258 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-ingredient supplementation
Number of subjects: 0
Study 31032258 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (control)
Number of subjects: 0
Study 31033034 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethylfumarate monotherapy
Number of subjects: 0
Study 31033034 — intervention group
Group type: COMPARATOR
Intervention: Fumaric acid ester mixture
Number of subjects: 0
Study 31033050 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning from the incubator to the crib
Number of subjects: 0
Study 31033050 — intervention group
Group type: COMPARATOR
Intervention: Control group (incubator care)
Number of subjects: 0
Study 31033194 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants stopped if d-dimer was negative
Number of subjects: 410
Study 31033194 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulants continued if d-dimer was positive
Number of subjects: 410
Study 31033443 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Happier app
Number of subjects: 128
Study 31033443 — intervention group
Group type: EXPERIMENTAL
Intervention: Calm app
Number of subjects: 128
Study 31033443 — intervention group
Group type: COMPARATOR
Intervention: Educational control
Number of subjects: 128
Study 31033623 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotope-labeled 3 mg aqueous zinc administered in the fasted state
Number of subjects: 40
Study 31033629 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time adherence feedback
Number of subjects: 59
Study 31034595 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with breast cancer receiving chemotherapy
Number of subjects: 376
Study 31034642 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted Hispanic Kidney Transplant Program
Number of subjects: 0
Study 31034642 — intervention group
Group type: COMPARATOR
Intervention: Standard care for kidney transplant
Number of subjects: 0
Study 31034676 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Questionnaire (DQ) utilizing proxy-based assessments
Number of subjects: 1260
Study 31034676 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAP cases inclusion
Number of subjects: 1260
Study 31034999 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 31034999 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 31035265 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography (EIT)
Number of subjects: 14
Study 31035291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten 10 to 20 mg/d (cohort A)
Number of subjects: 21
Study 31035291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten 2 to 5 mg/d with β-blockers (cohort B)
Number of subjects: 21
Study 31036012 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-biologic disease-modifying antirheumatic drugs (non-bDMARDs)
Number of subjects: 210
Study 31036012 — intervention group
Group type: COMPARATOR
Intervention: Biologic disease-modifying antirheumatic drugs (biologic DMARDs)
Number of subjects: 210
Study 31036012 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 210
Study 31036012 — intervention group
Group type: EXPERIMENTAL
Intervention: Retired patients at baseline
Number of subjects: 210
Study 31036014 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 2
Study 31036014 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of clinical and laboratory parameters
Number of subjects: 2
Study 31036014 — intervention group
Group type: COMPARATOR
Intervention: Thick blood smear microscopy
Number of subjects: 2
Study 31036014 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematological evaluations
Number of subjects: 2
Study 31036332 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frailty (measured by Clinical Frailty Scale)
Number of subjects: 321
Study 31036332 — intervention group
Group type: EXPERIMENTAL
Intervention: Major complications
Number of subjects: 321
Study 31036332 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor complications
Number of subjects: 321
Study 31036332 — intervention group
Group type: EXPERIMENTAL
Intervention: American Society of Anesthesiologists score
Number of subjects: 321
Study 31036332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hospitalization costs
Number of subjects: 321
Study 31036762 — intervention group
Group type: EXPERIMENTAL
Intervention: Connections between face-processing network and medial temporal lobe memory system (including the hippocampus) and social processing system.
Number of subjects: 50
Study 31036762 — intervention group
Group type: EXPERIMENTAL
Intervention: Face processing network interactions
Number of subjects: 50
Study 31036770 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 100 mg p.o. daily (continuous dosing)
Number of subjects: 25
Study 31036879 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-GITR-based combination immunotherapy
Number of subjects: 0
Study 31037275 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Tart Cherry Juice (TCJ)
Number of subjects: 0
Study 31037275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31037293 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric laser endomicroscopy (VLE)
Number of subjects: 1000
Study 31038467 — intervention group
Group type: EXPERIMENTAL
Intervention: Current patient monitoring systems
Number of subjects: 15
Study 31038467 — intervention group
Group type: EXPERIMENTAL
Intervention: Future patient monitoring systems
Number of subjects: 15
Study 31038467 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation of novel technology
Number of subjects: 15
Study 31038467 — intervention group
Group type: EXPERIMENTAL
Intervention: User-derived findings
Number of subjects: 15
Study 31038467 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital health technology
Number of subjects: 15
Study 31038469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 10 mg on visit 1
Number of subjects: 7
Study 31038469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 10 mg on visit 2
Number of subjects: 7
Study 31038469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 30 mg on visit 3
Number of subjects: 7
Study 31038469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine 50 mg on visit 4
Number of subjects: 7
Study 31038469 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sample drawn on visit 5
Number of subjects: 7
Study 31038781 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LDL-C below the target of 70 mg/dL
Number of subjects: 1482
Study 31038781 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 1482
Study 31038781 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with illiteracy
Number of subjects: 1482
Study 31038781 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who believe cholesterol treatment should be terminated when cholesterol normalizes
Number of subjects: 1482
Study 31038781 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician perceptions about LDL-C goal for secondary prevention
Number of subjects: 1482
Study 31039409 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) followed by allogeneic HSCT
Number of subjects: 101